Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded a decrease of -4.70%. However, over the last six months, the performance has been stronger by -13.08%. The price of BMY decreased -6.84% over the last 30 days. And in the last five days, it has fallen by -4.31%.
Bristol-Myers Squibb Co. experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $70.93 on 04/25/23, while the lowest price for the same period was registered at $47.58 on 02/06/24.
52-week price history of BMY Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Bristol-Myers Squibb Co.’s current trading price is -31.06% away from its 52-week high, while its distance from the 52-week low is 2.77%. The stock’s price range during this period has varied between$47.58 and $70.93. The Bristol-Myers Squibb Co.’s shares, which operate in the Healthcare, saw a trading volume of around 3.87 million for the day, a figure considerably lower than their average daily volume of 16.07 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Bristol-Myers Squibb Co. (BMY) has experienced a quarterly decline of -2.80% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 99.11B and boasts a workforce of 34100 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 50.79, with a change in price of -2.13. Similarly, Bristol-Myers Squibb Co. recorded 15,768,453 in trading volume during the last 100 days, posting a change of -4.19%.
BMY’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BMY stands at 1.41. Similarly, the long-term debt-to-equity ratio is also 1.30.
BMY Stock Stochastic Average
As of today, Bristol-Myers Squibb Co.’s raw stochastic average for the last 50 days stands at 15.16%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 9.28%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 3.26% and 3.40%, respectively.
